Skip to main content
Christopher M. Hull
( out of 650 reviews )

Christopher M. Hull, MD

Languages spoken: English, Spanish

Clinical Locations

Midvalley Health Center

Murray
801-581-2955

U of U Health Elko Specialty Clinic

Dermatology Outreach Clinic
Elko
801-581-2955

University of Utah Hospital

Dermatology, Area E
Salt Lake City
801-581-2955
  • Christopher Hull, MD has specialized expertise in the treatment of autoimmune skin diseases and viral infections of the skin. He is board certified in dermatology. His main clinical focus is general dermatology and medical dermatology including autoimmune blistering diseases.

    Board Certification

    American Board of Dermatology (Dermatology)
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 650 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    April 28, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Great doctor

    April 28, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Hull is an excellent Dermatologist. I would recommend him to anyone.

    April 27, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    He is very personable, professional, answering questions carefully. Enjoy a great derm.

    April 27, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    I've gone to Dr. Hull for years. He's very thorough, and very professional.

    April 26, 2024
    UH HOSPITALS AND CLINICS

    Meticulous in approach and demeanor, Dr. Hull¿s experience and expertise are manifest. I¿m very fortunate to be in his kind, conscientious care.

    April 24, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hull is extremely knowledgeable and very easy to talk to. He cured my horrible disease that other doctors had made worse and I trust his judgement completely. I feel very fortunate to have him as my doctor.

    April 23, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Hull is a consummate pro. He is always interested in my personal life and informative on my health. I have complete trust over a long period of time in Dr Hull

    April 13, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Hull is a wonderful doctor and so very kind and knowledgeable. Couldn¿t ask for anyone better.

    April 12, 2024
    UH HOSPITALS AND CLINICS

    Dr. Hull is an excellent physician who provides an extremely high level of care!

  • Christopher Hull, MD has specialized expertise in the treatment of autoimmune skin diseases and viral infections of the skin. He is board certified in dermatology. His main clinical focus is general dermatology and medical dermatology including autoimmune blistering diseases.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Internal Medicine -Adjunct
    Academic Divisions Infectious Diseases
    Board Certification
    American Board of Dermatology (Dermatology)
    National Board of Medical Examiners

    Education history

    Residency Dermatology - University of Utah School of Medicine Resident
    Internal Medicine - University of Utah School of Medicine Intern
    Professional Medical Medicine - University of Washington School of Medicine M.D.
    Universidad de Granada Baccalaureate
    Undergraduate Molecular & Cell Biology - University of Colorado - Boulder B.S.

    Selected Publications

    Journal Article

    1. Kern JA, Amanullah AA, Sahni DR, Mathis JG, Hull CM, Powell DL, Secrest AM (2023). Granulomatous cheilitis - is there a role for allergen screening and avoidance? J Dermatolog Treat, 34(1), 2171707. (Read full article)
    2. Hopkins ZH, Jimenez A, Taliercio VL, Clarke JT, Hansen CB, Hull CM, Rhoads JLW, Zone JJ, Sahni VN, Kean J, Secrest AM (2023). Skin-Related Quality of Life During Autoimmune Bullous Disease Course. JAMA Dermatol, 159(11), 1185-1194. (Read full article)
    3. Marcacci E, Truong A, Wu C, Presson AP, Lewis BKH, Hull CM (2023). Improving access to dermatologic care: A retrospective analysis of dermatology rural outreach clinics in Utah and Wyoming compared to an urban academic center. J Am Acad Dermatol. (Read full article)
    4. Hoshina Y, Wong KH, Galli J, Bacharach R, Klein J, Lebiedz-Odrobina D, Rose JW, Trump B, Hull C, Greenlee JE, Clardy SL (2023). Neurologic involvement in seronegative primary Sjögren's syndrome with positive minor salivary gland biopsy: a single-center experience. Front Neurol, 14, 1174116. (Read full article)
    5. Sahni D, Hull C, Grant GJ, Florell S, Wada D, Bowen A, Florell A (2022). An atypical case of eosinophilic pustular folliculitis with associated secondary follicular mucinosis treated with indomethacin. JAAD Case Rep.
    6. Amanullah AA, Sahni DR, Sahni VN, Hull CM, Powell DL, Secrest AM (2022). Reply to: current treatment modalities in granulomatous cheilitis. Int J Dermatol. (Read full article)
    7. Freeman C, Hull C, Sontheimer R, Curtis J (2020). Squamous cell carcinoma of the dorsal hands and feet after repeated exposure to ultraviolet nail lamps. Dermatol Online J, 26(3). (Read full article)
    8. Topham C, Haynes D, Frigerio A, Hull C (2019). Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. Pediatr Dermatol, 36(4), e102-e103. (Read full article)
    9. Varedi D, Frigerio A, Scaife C, Hull C (2019). A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. Dermatol Online J, 25(3). (Read full article)
    10. Hull CM, Levin MJ, Tyring SK, Spruance SL (2013). Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis. Antimicrob Agents Chemother, 58(3), 1273-8. (Read full article)
    11. McCaughey C, Machan M, Bennett R, Zone JJ, Hull CM (2011). Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. J Eur Acad Dermatol Venereol, 25(9), 1061-7. (Read full article)
    12. Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpo B, Levin MJ, Tyring S, Spruance SL (2011). Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol, 64(4), 696.e1-11. (Read full article)
    13. Hull CM, Brunton S (2010). The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis. Postgrad Med, 122(5), 1-6. (Read full article)
    14. Hull C, Spruance S (2007). Situational antiviral drug prophylaxis for HSV type 1 recurrences. Herpes, 14(2), 37-40. (Read full article)
    15. Zone JJ, Taylor T, Hull C, Schmidt L, Meyer L (2007). IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol, 127(5), 1167-74. (Read full article)
    16. Liddle M, Hull C, Liu C, Powell D (2006). Contact urticaria from curcumin. Dermatitis, 17(4), 196-7. (Read full article)
    17. Hull C, Spruance S, Tyring S, Hamed K (2006). Single-dose famciclovir for the treatment of herpes labialis. Curr Med Res Opin, 22(9), 1699-702. (Read full article)
    18. Hanson N, Hull C, Meyer L (2004). Fever and lymphadenopathy in a farmer. Arch Dermatol, 140(12), 1531-6. (Read full article)
    19. Hull C, Larson A, Leachman S (2003). Pharmacogenetic candidate genes for melanoma. Pharmacogenomics, 4(6), 753-65. (Read full article)

    Review

    1. Nguyen C, Kuceki G, Birdsall M, Sahni DR, Sahni VN, Hull CM (2024). Rosacea: Practical Guidance and Challenges for Clinical Management. [Review]. Clin Cosmet Investig Dermatol, 17, 175-190. (Read full article)
    2. Hull CM, Brunton S (2010). The Role of Topical 5% Acyclovir and 1% Hydrocortisone Cream (XereseTM) in the Treatment of Recurrent Herpes Simplex Labialis. [Review]. Postgrad Med, 122(5), 1-6.

    Book Chapter

    1. Hull C, Zone JJ (Published). Dermatitis herpetiformis and linear IgA bullous dermatosis. In Bolgnia J, Jorizzo (Eds.), Dermatology (3). Elsevier Mosby.

    Case Report

    1. Jimenez A, Topham C, Varedi D, Leiferman KM, Hull C (2021). Mucosal linear IgA disease with esophageal involvement responsive to ustekinumab. JAAD Case Rep, 15, 4-6. (Read full article)
    2. Jimenez A, Hull C, Zone J (2021). Rituximab therapy for a severe case of pretibial myxedema. JAAD Case Rep, 10, 28-30. (Read full article)
    3. Abbott J, Kowalski EH, Klein S, DeShazo R, Hull CM (2020). Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. JAAD Case Rep, 6(3), 181-183. (Read full article)
    4. Jimenez A, Hull C, Zone J (2019). Dermatitis herpetiformis resistant to dapsone due to dietary iodide ingestion. JAAD Case Rep, 5(8), 713-714. (Read full article)

    Letter

    1. Ali NS, Sahni VN, Ma BC, Sahni DR, Hull CM, Powell DL, Secrest AM (2021). Reply to: low response of granulomatous cheilitis to currently established treatments. [Letter to the editor]. J Eur Acad Dermatol Venereol, 35(12), e930-e931. (Read full article)
    2. Westerdahl S, Hull CM, Clarke JT, Hansen CB, Rhoads JLW (2020). A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation. [Letter to the editor]. J Am Acad Dermatol, 84(2), 559-561. (Read full article)
    3. Truong A, Laggis CW, Annis TD, Secrest AM, Fino NF, Powell DL, Gardner LJ, Gregory T, Hull CM, Lewis BKH (2019). Factors associated with follow-up adherence in patients seen at a referral-based dermatology clinic for the homeless. [Letter to the editor]. J Am Acad Dermatol, 83(2), 629-631. (Read full article)
    4. Harris K, Vanderhooft L, Burt L, Vanderhooft S, Hull C (2011). Tanning business practices in Salt Lake County, Utah. [Letter to the editor]. J Am Acad Dermatol, 66(3), 513-4. (Read full article)